VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 ...
In a groundbreaking study published in the journal Genes & Diseases, researchers from University of Electronic Science and Technology of China have uncovered a key relationship between the EMC1 ...
– Additional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion; reporting rate is in line with other ...
In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...
Researchers have identified novel retinal vascular signatures that are significantly associated with the risk for a first stroke. When combined with age and sex, these retinal “fingerprints” predicted ...
NovaBridge Biosciences and Visara have announced topline results from their phase 2a study of VIS-101 for retinal vascular ...
A Nasdaq-listed biotechnology company repositioned as a global platform for acquiring and advancing clinical-stage assets. NovaBridge Biosciences is built around two principal programs, givastomig in ...
Everest Medicines (HKEX: 1952.HK) today announced that its licensing partner, NovaBridge Biopharma (NASDAQ: NBP, "NovaBridge"), together with its subsidiary Visara, Inc. ("Visara"), reported positive ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results